#United States #Needham #Stealth BioTherapeutics #Elamipretide #POLG disease

Stealth BioTherapeutics to Present at Euromit 2026

Stealth BioTherapeutics, known for its innovative approaches in biotechnology, is gearing up for a pivotal moment as it announces its presentations at the International Meeting on Mitochondrial Pathology (Euromit). This significant event is scheduled to take place from May 31 to June 4, 2026, in Angers, France, and will focus on groundbreaking topics concerning mitochondrial diseases.

At the forefront of Stealth's presentations is the design for a confirmatory study of elamipretide in patients with Barth syndrome. This rare genetic condition is characterized by various health challenges, including severe muscle weakness and heart complications. Alongside this, the company plans to share compelling clinical and preclinical findings that bolster the case for elamipretide as a treatment option for mitochondrial myopathy caused by polymerase gamma (POLG) mutations, which have long left patients with limited treatment alternatives.

Reenie McCarthy, Chief Executive Officer of Stealth BioTherapeutics, expressed a strong commitment to enhancing the landscape of treatments available for those affected by mitochondrial disease. “We are dedicated to advancing a novel class of medicines that can transform the lives of individuals living with these conditions,” McCarthy stated. The collaboration with scientific stakeholders and the affected community during the conference aims to chart fruitful pathways for the further development of elamipretide.

The implications of POLG disease are severe and multifaceted, as highlighted by Dr. Mary Kay Koenig, a noted pediatric neurologist. She described the illness as a tragic genetic disorder that can result in multi-organ failure, emphasizing that the current medical landscape offers little beyond symptomatic management. The Phase 3 results from Stealth's NuPOWER trial underline the potential of elamipretide for those with POLG1 mutations, making the development of targeted studies in this area increasingly critical.

During Euromit, various presentations will delve into distinct aspects of elamipretide's efficacy. The presentations are scheduled as follows:
1. Flash Talk and Poster titled "Elamipretide Clinical Manifestations and Phase 3b/4 Confirmatory Trial" presented by Anthony Abbruscato, Senior VP of Clinical Development, on June 4, from 1:25 PM to 3:00 PM.
- Abstract Number: 00276
- Location: Angers Convention Centre
- Session: Therapeutic and Diagnostic Developments

2. Poster presentation titled "NuPOWER – Phase 3 Study of Elamipretide in Subjects with Primary Mitochondrial Disease Overall Outcomes" by Dr. Mary Kay Koenig, also on June 4, at the same time and location.
- Abstract Number: 00302
- Session: Therapeutic and Diagnostic Developments

3. Another Flash Talk and Poster titled "Beneficial Effects of Elamipretide in Preclinical Models of POLG Disease" led by David A. Brown, Chief Scientific Officer, on June 4, from 1:25 PM to 3:00 PM.
- Abstract Number: 00259
- Location: Angers Convention Centre
- Session: Therapeutic and Diagnostic Developments

As the leading international congress dedicated to mitochondrial disease research, Euromit serves as an essential venue for connecting researchers, clinicians, and stakeholders focused on advancing treatments for these complex diseases.

About Barth Syndrome

Barth syndrome is an ultra-rare genetic disorder resulting from mitochondrial dysfunction. It typically manifests through symptoms like exercise intolerance, heart failure, and increased susceptibility to infections. Life expectancy is drastically reduced, with many affected individuals not surpassing early childhood.

Insights into Stealth BioTherapeutics

Stealth is dedicated to developing pioneering therapies to enhance the quality of life for patients suffering from mitochondrial disorders. Following an accelerated approval for its first commercial product by the FDA in September 2025, the company is continuously exploring new indications for elamipretide and further expanding its pipeline with candidates like bevemipretide, addressing both ophthalmic and neurological conditions.

In conclusion, Stealth BioTherapeutics’ upcoming presentations at Euromit 2026 represents a crucial step forward in the quest to provide innovative and effective treatments for those battling the challenges of mitochondrial diseases.